

IMMEDIATE COMMUNICATION OPEN



Rare tandem repeat expansions associate with genes involved in synaptic and neuronal signaling functions in schizophrenia

Jia Wen^{1,13}, Brett Trost^{2,3,13}, Worrawat Engchuan^{2,3,13}, Matthew Halvorsen¹, Linda M. Palotto², Aleksandra Mitina², NaEshia Ancalade¹, Martilias Farrell¹, Ian Backstrom², Keyi Guo², Giovanna Pellicchia^{2,3}, Bhooma Thiruvahindrapuram^{2,3}, Paola Giusti-Rodriguez⁴, Jonathan David Rosen¹, Yun Li^{1,5}, Hyejung Won¹, Patrik K. E. Magnusson⁶, Ulf Gyllenstein⁷, Anne S. Bassett^{8,9,10}, Christina M. Hultman⁶, Patrick F. Sullivan^{1,6,11}, Ryan K. C. Yuen^{2,12,14} and Jin P. Szatkiewicz^{1,11,14}

© The Author(s) 2022

Tandem repeat expansions (TREs) are associated with over 60 monogenic disorders and have recently been implicated in complex disorders such as cancer and autism spectrum disorder. The role of TREs in schizophrenia is now emerging. In this study, we have performed a genome-wide investigation of TREs in schizophrenia. Using genome sequence data from 1154 Swedish schizophrenia cases and 934 ancestry-matched population controls, we have detected genome-wide rare (<0.1% population frequency) TREs that have motifs with a length of 2–20 base pairs. We find that the proportion of individuals carrying rare TREs is significantly higher in the schizophrenia group. There is a significantly higher burden of rare TREs in schizophrenia cases than in controls in genic regions, particularly in postsynaptic genes, in genes overlapping brain expression quantitative trait loci, and in brain-expressed genes that are differentially expressed between schizophrenia cases and controls. We demonstrate that TRE-associated genes are more constrained and primarily impact synaptic and neuronal signaling functions. These results have been replicated in an independent Canadian sample that consisted of 252 schizophrenia cases of European ancestry and 222 ancestry-matched controls. Our results support the involvement of rare TREs in schizophrenia etiology.

Molecular Psychiatry; <https://doi.org/10.1038/s41380-022-01857-4>

INTRODUCTION

Schizophrenia is a chronic and debilitating mental disorder. Twin, family, and adoption studies consistently support a genetic basis for schizophrenia, with estimates of heritability in the range of 60–65% from pedigree data, and around 81% from twin data [1–3]. Tremendous progress has been made toward the identification of genetic variants that confer schizophrenia risk, including 270 loci harboring common variants, 8 large rare copy number variants, and 10 genes implicated from exome sequencing studies of rare coding variants [4–6]. Nonetheless, the genetic variants identified thus far for schizophrenia confer less risk than its heritability estimates [4–6]. Tandem repeats are a plausible source for some of this missing heritability [4, 7, 8]; however, until recently tandem repeats were difficult to interrogate due to the technical difficulty of resolving complex variants in repetitive regions from short-read sequencing [4] and in genotyping/imputing tandem repeats using biallelic SNP arrays.

Tandem repeats occur in DNA where sequences of one or more nucleotides are repeated directly adjacent to each other. They are

a major source of genetic variation in the human genome [9, 10]. The repetitive sequence in a tandem repeat can cause DNA slippage during DNA replication or repair, leading to increases in repeat size across generations. Pathogenic tandem repeat expansions (TREs) are currently known to cause over 60 disorders, most of which affect the central nervous system [7, 11–13]. TREs can alter both coding and non-coding regions of genes and exert harmful effects via a variety of pathophysiological mechanisms (reviewed in [7, 12]). TREs in the coding sequence can result in abnormally long stretches of polyglutamine or polyalanine, leading to protein misfolding and aggregation (e.g., expanded CAG repeats in *HTT* in Huntington's disease). TREs in the noncoding sequence can occur in 5' or 3' untranslated regions (UTRs), introns, promoters, or enhancers. The impact of noncoding TREs depends on the type, length, and locations of the repeats, which may include epigenetic gene silencing, RNA toxicity mediated by protein titration, repeat-associated non-AUG translation, modulation of enhancer activity, and disruptions of boundaries demarcating 3D chromatin domains [7, 12–15].

¹Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA. ²Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada. ³The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada. ⁴Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL 32610, USA. ⁵Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, USA. ⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden. ⁷Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala 75185, Sweden. ⁸Clinical Genetics Research Program and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M6J 1H4, Canada. ⁹The Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto General Hospital, and Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada. ¹⁰Department of Psychiatry, University of Toronto, Toronto, ON M5S 1A8, Canada. ¹¹Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599, USA. ¹²Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada. ¹³These authors contributed equally: Jia Wen, Brett Trost, Worrawat Engchuan. ¹⁴These authors jointly supervised this work: Ryan K. C. Yuen, Jin P. Szatkiewicz. ✉email: ryan.yuen@sickkids.ca; jin_szatkiewicz@med.unc.edu

Received: 22 February 2022 Revised: 14 October 2022 Accepted: 24 October 2022

Published online: 16 November 2022

Due to their repetitiveness and abundance in the human genome, tandem repeats are challenging to study at a genome-wide scale [7]. Recent studies by Trost et al. and Mitra et al. developed computational methods to evaluate genome-wide tandem repeats in autism spectrum disorder (ASD) using data generated from short-read whole genome sequencing (WGS), and together they provide compelling evidence that TREs contribute to ASD susceptibility [16, 17]. For schizophrenia, genome-wide evaluations of tandem repeats are now emerging [18]. Published WGS studies examined TREs in a number of specific loci known to be associated with monogenic neurological diseases and found several of these variants in schizophrenia patients [19, 20]. In an attempt to identify causative variants underlying *CACNA1C*, one of the loci being replicated in multiple common variant associations for schizophrenia and bipolar disorder, Song et al. found that an intronic tandem repeat was associated with a higher risk of developing psychiatric disorders and decreased enhancer activity [21]. Most recently, Mojarad et al. applied methods developed in ASD studies and evaluated genome-wide tandem repeats in 252 schizophrenia cases and 222 controls [18]. Despite their relatively small sample size, the results from Mojarad et al. suggest that rare TREs are an important class of variants contributing to the etiology of schizophrenia. These examples, as well as the known genetic overlap between schizophrenia and ASD [22, 23], highlight the need for further systematic investigations of TREs in schizophrenia.

In this study, we carry out a genome-wide investigation in the role of rare TREs in schizophrenia etiology. We first apply a genome-wide TRE detection pipeline [16] to identify TREs from WGS data in a Swedish sample of schizophrenia cases and controls. We then assess the possible functional effects of these variants by comparing burdens of rare TREs between cases and controls in genic and intergenic regions, in different parts of genes, in gene-sets previously identified to increase risk for schizophrenia or neurodevelopmental disorders, as well as in conserved sequences and epigenomic annotations empirically derived from the human brain. Finally, we replicate significant associations in an independent Canadian cohort [18]. Our results suggest that rare TREs collectively contribute to the genetic risk of schizophrenia.

MATERIALS AND METHODS

Subject recruitment and ethics approval

We have complied with all relevant ethical regulations. The study protocol and all procedures on data from human research subjects were approved by the appropriate ethical committees in Sweden and the United States (Karolinska Institutet [Regionala Etikprövningsnämnden, Stockholm], University of Uppsala [Regionala Etikprövningsnämnden, Uppsala], and University of North Carolina Institutional Review Boards). All participants gave written informed consent.

The primary WGS dataset used in this study consists of 1159 Swedish schizophrenia cases and 936 ancestry-matched population control individuals [19]. Full descriptions of the cohort are available elsewhere [19] and are briefly summarized here. The schizophrenia cases were selected from the Swedish Schizophrenia Study [24] to have typical Swedish ancestry, unequivocal schizophrenia case status (>8 inpatient or outpatient psychiatric treatment contacts for schizophrenia or schizoaffective disorder, ≥30 inpatient days for schizophrenia, ≥5 redeemed prescriptions for antipsychotics, and few or no treatment contacts for bipolar disorder), and without any known pathogenic CNVs (e.g., 22q11.2 deletion). Carriers of known pathogenic CNVs were previously identified from SNP array genotyping [25] and were not included in this study because here we aim to evaluate the contribution of novel loci to schizophrenia risk. Controls were group matched to cases by ancestry and were selected from the SweGen project (unrelated individuals originating from the Swedish Twin Registry [26]). We also included WGS data derived from 2504 unrelated samples from the phase three panel of the 1000 Genomes Project (1000GP [27]). The 1000GP cohort included individuals from 26 populations, representing five continental regions of the world.

Whole genome sequencing data

Individuals from the schizophrenia case-control cohort were previously sequenced by our group at the National Genomics Infrastructure platform in Sweden [19]. DNA was extracted from blood. DNA libraries were prepared from ~1 µg DNA using Illumina TruSeq PCR-free DNA sample preparation kits targeting an insert size of 350 bp in accordance with the manufacturer's instructions. Libraries were sequenced on the Illumina HiSeq X platform using 2 × 150 base pair (bp) cycles (2 × 150 bp paired-end reads) to a target depth of 30x (minimum 21x, median 37x). The 1000GP sample collection was sequenced by The New York Genome Center [27]. DNA was extracted from lymphoblastoid cell lines. DNA libraries were prepared from 1 µg DNA using the Illumina TruSeq DNA PCR-free (450 bp) Library Preparation Kit in accordance with the manufacturer's instructions. Libraries were sequenced on an Illumina NovaSeq 6000 sequencer using 2 × 150 bp cycles to a target depth of 30x (minimum 27x, mean 34x).

Genome-wide detection of tandem repeats, TREs, and rare TREs

We used ExpansionHunter Denovo (EHdn) [28], an efficient catalog-free method for genome-wide tandem repeat detection from short-read WGS data. We applied the density-based spatial clustering of applications with noise (DBSCAN) algorithm to identify TREs whose lengths were outliers compared with other members of the cohort [16, 29]. We defined rare TREs as TREs that were found in less than 0.1% of the 1000GP population controls. All genomic coordinates are given in NCBI Build 38/UCSC hg38. A detailed description of the detection methods is provided in Supplementary Methods.

Statistical analyses

A detailed description of quality control, genome annotations and statistical analyses is provided in Supplementary Methods.

Gel electrophoresis

Selected tandem repeats predicted by EHdn were validated with gel electrophoresis size separation of PCR products of the regions of interest. The following coordinates (hg38) were amplified using the reagents, primers, and conditions specified. Takara PrimeSTAR GXL DNA Polymerase (GXL) and Qiagen HotStarTaq DNA Polymerase (HotStar) kits were used. General thermocycling conditions are as follows: GXL - 1 min 98 °C, 37x (10 s 98 °C, 15 s variable, 1 min 30 s 68 °C), 10 min 68 °C. HotStar - 15 min 95 °C, 37x (30 s 95 °C, 30 s variable, 1 min 15 s 72 °C), 10 min 72 °C. Target specific information: *PDI5* chr3:123151603-123152369, F-GCCTTCATAGC AGACATAAGCC, R - TCTGCCAGAGTTGAGTCAC, HotStar with Q solution, Anneal 63 °C; *GABRA1* chr5:161663263- 161663867, F - GCAAGAAAGGGA GTTACCG, R - CCTAACACCTCATGCTGTACC, GXL, Anneal 60 °C. The sample NA12878 available from Coriell was used as the reference control. A 100 bp ladder was used for size reference (FroggaBio 100 bp).

Replication

We obtained replication association results from an independent dataset from Canada that included 252 unrelated adult cases with schizophrenia of European ancestry and 222 ancestry-matched individuals with no major neuropsychiatric disorders (after removal of 8 samples being outliers of genome-wide tandem repeat count) [18]. This dataset is well-suited for replication because the sequencing technology and TRE detection methods used for the replication samples were identical to those used for our Swedish case-control samples. Replication was attempted for all significant association results in the Swedish case-control comparisons. For each attempted region, we performed burden testing of rare TREs in cases versus controls in the replication samples and obtained association summary statistics. We then used METAL [30] to perform a fixed-effect meta-analysis using the inverse-variance-based method to merge the findings between the original and the replication studies. Details of the replication samples, TRE detection, quality control and statistical analyses are documented in Supplementary Methods.

RESULTS

We used WGS data from 1159 schizophrenia cases and 936 ancestry-matched population controls from Sweden that were previously generated by our group [19] (Fig. 1). To estimate population frequency of tandem repeats, we included WGS data




Fig. 1 Study overview. This flowchart summarizes the study design and analytic workflow.

for 2504 genomes sequenced by the 1000 GP [27]. All WGS data were sequenced on Illumina platforms using 150 bp paired-end reads to a similar mean coverage per sample.

Identification of novel tandem repeats expanded in schizophrenia

Using EHdn [28] we performed genome-wide detection of tandem repeats that have motifs between 2 and 20 bp and total length greater than the read length (150 bp) across all the samples. Seven samples (5 schizophrenia cases and 2 controls) were removed because they were outliers in terms of genome-wide tandem repeat count (Supplementary Fig. 1), resulting in 4592 genomes for subsequent analyses (1154 schizophrenia cases, 934 controls, and 2504 samples from 1000GP).

We defined a tandem repeat-containing region as a genomic location containing tandem repeats with one or more different motifs overlapping by at least 1 bp. Across all 4592 samples, we identified 21,153 unique tandem repeat motifs in 16,723 distinct regions (Supplementary Table 1). The technical characteristics of our tandem repeat data, including the distributions of motif, motif size, and tandem-repeat-containing regions, were consistent with those reported previously [16, 18] (Supplementary Figs. 2–4). Tandem-repeat-containing regions were enriched in GC-rich regions (odds ratio [OR] = 1.04, $P < 2.2e-16$) but depleted in conserved DNA sequences defined by phyloP [31] (OR = 0.015, $P < 2.2e-16$) and phastCons [32] (OR = 0.208, $P < 2.2e-16$, Supplementary Table 2, Supplementary Fig. 5). We compared our data to the known simple sequence repeat regions in the human reference genome and to tandem repeat loci reported in ASD [16]. Of the 16,723 tandem-repeat-containing regions reported here, 3447 (20.6%) of them have not been previously reported (Supplementary Fig. 6).

Pathogenic TREs are typically significantly longer than what is observed in the general population. For example, patients with fragile X syndrome typically carry >200 CGG repeats in the 5' UTR of *FMR1*, while unaffected individuals generally have 6 to 53 repeats. Following Trost et al. [16], we defined a TRE as a tandem repeat that is much larger than most other members of the study cohort. We applied DBSCAN [29], a non-parametric clustering

algorithm, to tandem repeat calls across the 4592 post-QC samples. Outliers for repeat length of each tandem repeat motif were deemed to be TREs. A total of 2890 TREs were identified, and 1559 (53.9%) of those were novel in comparison to the TREs reported in Trost et al. [16].

We deemed TREs in the schizophrenia case-control cohort to be rare when found in less than 0.1% of the 1000 GP samples. This resulted in 603 rare TREs for subsequent burden testing (Supplementary Table 3). We examined the distribution of the count of rare TREs per sample using a stratified histogram (Supplementary Fig. 7). We did not observe any samples that were outliers based on rare TRE count (Supplementary Fig. 7).

Contribution of rare tandem repeat expansions in schizophrenia

To assess the possible functional effects of rare TREs, we used burden testing to evaluate whether rare TREs are enriched in different genomic annotations in schizophrenia cases versus controls. Only autosomal TREs were retained for burden analysis. Our power calculation suggested that we had $\geq 80\%$ power to detect association signals with burden testing when the aggregated minor allele frequency was 0.01 (i.e. aggregated minor allele count of 20), the genotypic relative risk was ≥ 4.9 , and assuming a type I error level of 1×10^{-5} (Supplementary Fig. 8). Burden testing was performed using logistic regression models that allowed us to correct for confounding factors that may cause spurious association signals as described in Supplementary Methods. To identify potential confounding variables, we carried out a principal component (PC) analysis of the normalized anchored in-repeat-read counts which suggested the inclusion of PC2, PC3, and PC8 as covariates in the logistic regression models (Supplementary Fig. 9 and Supplementary Table 4). After correcting for these PCs along with sex, we did not find evidence of inflation based on the estimated effect measured by the burden of rare TREs in intergenic regions (see below *Genome-wide burden*), which is consistent with a prior report [16]. Furthermore, for burden testing in target regions (i.e. global genic regions, gene parts, gene sets, epigenomic annotations), we additionally included global intergenic burden as a covariate in the logistic




Fig. 2 Genome-wide burden of rare TREs in schizophrenia. The error bars denote 95% confidence interval.

regression models to correct for any confounding factors that may have not been accounted for by the PC2, PC3, and PC8, and to increase the specificity of the tests in target regions.

Genome-wide burden. We first compared the total number of rare TREs in schizophrenia cases versus controls in three ways: genome-wide, in genic regions only, and in intergenic regions only. When a rare TRE overlapped with any gene/transcript by at least 1 bp, it was defined as genic; otherwise, it was intergenic. We observed a significantly increased burden in schizophrenia for rare TREs (OR = 1.403, $P = 0.004$) and genic rare TREs (OR = 1.549, $P = 0.003$; Fig. 2). No statistically significant difference between cases and controls was detected for rare TREs in intergenic regions (OR = 1.182, $P = 0.232$; Fig. 2). To understand how repeat motifs may influence case-control burden comparison, we stratified genic TREs into CpG-containing (any rare genic TRE that contains the sequence of CG, GC, CGC, CGG, CCG, GCC, GGC or GCG) or non-CpG-containing, and performed burden testing for each group separately. There were 249 CpG-containing rare genic TREs and 694 non-CpG-containing rare genic TREs across 1,154 schizophrenia and 934 control samples. The burdens of both CpG-containing and non-CpG-containing genic rare TREs were significantly increased in schizophrenia cases compared to controls. (Supplementary Table 5).

Given our finding that tandem repeats were depleted in conserved DNA sequences, we next compared the total conserved base pairs affected by rare TREs in cases versus controls and observed a modestly elevated burden in schizophrenia (OR = 1.005, $P = 0.021$; Supplementary Table 6). We further performed burden analysis for coding conserved base pairs and non-coding conserved base pairs separately and found that the elevated burden is significantly contributed by conserved base pairs in non-coding regions (Supplementary Table 6).

We estimated the proportion of samples carrying rare TREs using the residuals of rare TRE counts after controlling for confounding factors. Using this approach, the estimated sample proportions were 11.35% in schizophrenia cases and 4.39% in controls, i.e., a 6.96% excess in schizophrenia (Wilcoxon ranked sum test $P = 8.83e-9$).

Burden in different parts of genes. Previous studies found that, in ASD, rare exonic TREs and rare TREs affecting splicing were enriched, while *de novo* tandem repeat mutations were enriched in brain regulatory regions [16, 17]. Motivated by these examples, we first compared the total number of rare TREs in schizophrenia cases versus controls in different parts of protein coding genes (Fig. 3 and Supplementary Table 7). Interestingly, we found a higher burden of rare intronic (OR = 1.436, $P = 0.030$) and rare splicing TREs (OR = 2.174, $P = 0.024$), although the excess was not statistically significant after multiple testing correction (BH-corrected $P = 0.105$ for both).

Burden in brain epigenomic annotations. We then compared the total number of rare TREs in schizophrenia cases versus controls within functional annotations experimentally derived from human brain tissue known to affect gene expression (Supplementary Table 8). These annotations include open chromatin regions from ATAC-seq [33], chromatin binding factor CTCF from ENCODE [34], boundaries of topologically associating domains (TADs) [35] including level 1 sub-TAD boundaries and level 2 sub-TAD boundaries, differential neuronal cell specific histone modifications (H3K27ac and H3K4me3) peaks [36], neuronal frequently interacting regions (FIRE, superFIRE) [37], and neuronal chromatin interactions [37]. The bin size was 40 kb for sub-TADs and FIRES, 10 kb for enhancer-promoter annotations, and for the remaining annotations ranged from 0.126 kb to 880 kb. We leveraged neuronal annotations when available as previous work has indicated neurons as the central cell type harboring genetic risk for schizophrenia [5, 36–38]. We observe a higher burden of rare TREs in sub-TAD boundaries – level 1 (OR = 4.977, $P = 0.012$), sub-TAD boundaries – level 2 (OR = 4.476, $P = 0.022$), and enhancer-promoter anchors (OR = 1.506, $P = 0.026$) in schizophrenia cases, but they were not statistically significant after multiple testing correction (BH-corrected $P = 0.105$, Supplementary Table 8).

Burden in gene sets previously implicated in schizophrenia and neurodevelopmental disorders. In fragile X syndrome, both abnormally expanded CGG repeats and point mutations in *FMR1* have been reported [39]. Motivated by this example, we hypothesized that schizophrenia-associated TREs may be enriched in genes known to increase risk for schizophrenia, previously identified via common variant association [5], copy number variation [4], exome sequencing [6], or gene expression studies [40, 41]. Given the known genetic overlap between schizophrenia and ASD [22, 23], we also included risk genes previously implicated in neurodevelopmental disorders via exome sequencing [42–44], copy number variation [45–47] or tandem repeats studies [6]. Burden testing compared the total number of rare TREs in cases versus controls within each of the 21 gene sets considered (Methods, Supplementary Table 9). We found an excess of rare TREs in schizophrenia cases in brain-expressed genes that are differentially expressed (DEGs) between schizophrenia and controls as determined by the Common Mind Consortium (i.e. CMC brain DEGs; OR = 6.63, $P = 0.005$, BH-corrected $P = 0.063$), the genes with expression quantitative trait loci (eQTLs) in human brain as identified by PsychENCODE Integrative Analysis (OR = 1.73, $P = 2.14e-3$, BH-corrected $P = 0.063$), as well as in the SynGO ontology category postsynapse process (OR = 27.94, $P = 0.004$, BH-corrected $P = 0.063$). These are further supported by the fact that many of the CMC brain DEGs with rare TREs and the genes with brain eQTLs overlapping with CMC brain DEGs are highly connected with other known schizophrenia genes and they are involved in similar functions in synaptic or neuronal signaling (Fig. 3). While examining specific genes within the three significant gene sets, we found that the rare TREs mostly affected introns (Supplementary Table 10).

To further explore the potential mechanisms by which TREs may regulate the underlying genes, we compared the level of




Fig. 4 Constraint scores for genes with and without rare TREs. Constraint scores (extracted from gnomAD's observed/expected (o/e) upper bound LOEUF values) of genes with rare TREs are compared against those of the other genes without rare TREs in schizophrenia. **A** Only genes differentially expressed between schizophrenia and controls as determined by the Common Mind Consortium are compared, **B** only genes with eQTL are compared and **(C)** comparison is done for all protein coding genes. Box plots show Q1-1.5×IQR, Q1, median, Q3 and Q3 + 1.5×IQR. P-values reported were calculated from one-sided Wilcoxon rank-sum test assuming lower gnomAD o/e upperbound in genes with rare TREs. In all three categories assessed, the genes with rare TREs found in schizophrenia were more constrained (i.e., had on average lower LOEUF values) than the genes without rare TREs found in schizophrenia.




Fig. 5 Confirmation of EHdn detected tandem repeats. **A, B**, Images of the gel electrophoresis showing bands that correspond to the expanded alleles in schizophrenia (SCZ) cases and the unexpanded allele in the reference sample NA12878. A 100 bp ladder is shown for size reference.

noteworthy however that the risk estimation from rare TREs in ASD was based on comparison of sample proportions between affected probands and unaffected siblings within families, while our risk estimation in schizophrenia was based on comparison of sample proportions between unrelated individuals. The risk estimation in ASD may be more conservative as some unaffected siblings within ASD families may have inherited shorter, yet expanded, tandem repeats [16]. Apart from the comparable collective contributions from rare TREs to ASD and schizophrenia, we did not identify with statistical significance TRE gene-pathways shared between ASD and schizophrenia, though we were likely underpowered to detect small enrichment given the rarity of the variants.

Our finding that rare TREs are enriched in schizophrenia in brain expressed genes with eQTLs or with different expression levels between schizophrenia cases and controls is not surprising. Tandem repeats can directly affect coding sequences or play an important role in the regulation of gene expression via a variety of mechanisms [7, 12]. The functional profiles of the implicated

genes were found to involve synaptic functions and signaling which is consistent with a prior report of tandem repeats in schizophrenia [18]. Our finding that genes with TREs tend to be more constrained is consistent with the literature [18] and suggests that TREs may affect the underlying genes in the same manner as loss of function variants. Our finding that rare TREs are enriched in schizophrenia in genes involved in postsynapse process, a gene set indicated by the largest schizophrenia GWAS [5], suggests that studies of tandem repeats may pinpoint shared underlying biology that is dysregulated across the spectrum of variant type and allele frequency. As our present study is correlative, a future direction would be to test the role of schizophrenia-associated TREs in patient-derived stem cells and model organisms in order to understand their precise functional effects on gene expression.

Although we observed a mildly elevated burden of rare TREs in schizophrenia in non-coding conserved bases, we did not identify significant enrichment of rare TREs within various categories of active regulatory elements in human brain. We note that there may be a disproportionately low representation of regions containing tandem repeats in currently available functional genomic annotations. For example, the use of exclusive regions of “blacklists” have been employed by the ENCODE project to remove signal artifact regions in next-generation sequencing experiments [34, 49]. These blacklisted regions may be due to repetitive elements or other anomalies where genome assembly has been difficult resulting in problematic read alignment and erroneous signals. Such blacklist filtering is a widely-used quality control step for functional genomics assays.

We acknowledge several constraints in variant detection owing to limitations in existing algorithms. First, EHdn detects tandem repeats only with motifs of 2-20 bp and total length larger than >150 bp. We were unable to evaluate tandem repeats with motif size or total length beyond the detection ranges. Second, as demonstrated by Trost et al. [16], EHdn likely underestimated the number of repeat units for larger tandem repeats when the total length of a tandem repeat is greater than the sequencing insert

size (approximately 350 bp for the Swedish schizophrenia cohort). Third, very small expansions, such as expansions with one or two additional repeat units, are missed. A few such small TREs, such as those found in spinocerebellar ataxia types 1, 2, and 6, are known to be disease causing [7, 50]. Fourth, our method does not resolve zygosity or orientation of the tandem repeats (only an aggregated length was estimated).

With the current sample size, we lack the power to detect individual tandem repeat loci that are associated with schizophrenia risk at genome-wide significance. Prior studies in ASD that had sample size larger than ours but in similar magnitude (~2000 cases) also failed to implicate individual loci of tandem repeats with ASD risk [16, 17]. Much larger cohorts (on the order of $N_{\text{case/control}} > 10,000$), combined with future improvements in variant detection methods, will likely pinpoint specific tandem repeat loci [19]. Substantial collaborative efforts will be critical in the pursuit of larger sample sizes. Our data are meant to be included through such collaborative efforts in the future in meta-analyzing whole genome sequence datasets in schizophrenia and other psychiatric disorders.

REFERENCES

- Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry*. 2003;60:1187–92.
- Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet*. 2009;373:234–9.
- Wray NR, Gottesman II. Using summary data from the danish national registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder. *Front Genet*. 2012;3:118.
- Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet*. 2017;49:27–35.
- Trubetsky V, Pardin AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*. 2022;604.
- Singh T, Poterba T, Curtis D, Akil H, Al Eissa M, Barchas JD, et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. *Nature*. 2022;604:509–16.
- Depienne C, Mandel JL. 30 years of repeat expansion disorders: What have we learned and what are the remaining challenges? *Am J Hum Genet*. 2021;108:764–85.
- Hannan AJ. Repeat DNA expands our understanding of autism spectrum disorder. *Nature*. 2021;589:200–2.
- Gymrek M. A genomic view of short tandem repeats. *Curr Opin Genet Dev*. 2017;44:9–16.
- Willems T, Gymrek M, Highnam G, Genomes Project C, Mittelman D, Erlich Y. The landscape of human STR variation. *Genome Res*. 2014;24:1894–904.
- Hannan AJ. Tandem repeats mediating genetic plasticity in health and disease. *Nat Rev Genet*. 2018;19:286–98.
- Usdin K. The biological effects of simple tandem repeats: lessons from the repeat expansion diseases. *Genome Res*. 2008;18:1011–9.
- Gall-Duncan T, Sato N, Yuen RKC, Pearson CE. Advancing genomic technologies and clinical awareness accelerates discovery of disease-associated tandem repeat sequences. *Genome Res*. 2022;32:1–27.
- Grunewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, et al. Chimeric EWSR1-FL11 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. *Nat Genet*. 2015;47:1073–8.
- Sun JH, Zhou L, Emerson DJ, Phyto SA, Titus KR, Gong W, et al. Disease-associated short tandem repeats co-localize with chromatin domain boundaries. *Cell*. 2018;175:224–38 e215.
- Trost B, Engchuan W, Nguyen CM, Thiruvahindrapuram B, Dolzhenko E, Backstrom I, et al. Genome-wide detection of tandem DNA repeats that are expanded in autism. *Nature*. 2020;586:80–86.
- Mitra I, Huang B, Mousavi N, Ma N, Lamkin M, Yanicky R, et al. Patterns of de novo tandem repeat mutations and their role in autism. *Nature*. 2021;589:246–50.
- Mojarad BA, Engchuan W, Trost B, Backstrom I, Yin Y, Thiruvahindrapuram B, et al. Genome-wide tandem repeat expansions contribute to schizophrenia risk. *Mol Psychiatry*. 2022:1–7.
- Halvorsen M, Huh R, Oskolkov N, Wen J, Netotea S, Giusti-Rodriguez P, et al. Increased burden of ultra-rare structural variants localizing to boundaries of topologically associated domains in schizophrenia. *Nat Commun*. 2020;11:1842.
- Mojarad BA, Yin Y, Manshaei R, Backstrom I, Costain G, Heung T, et al. Genome sequencing broadens the range of contributing variants with clinical implications in schizophrenia. *Transl Psychiatry*. 2021;11:84.
- Song JHT, Lowe CB, Kingsley DM. Characterization of a Human-Specific Tandem Repeat Associated with Bipolar Disorder and Schizophrenia. *Am J Hum Genet*. 2018;103:421–30.
- Brainstorm C, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, et al. Analysis of shared heritability in common disorders of the brain. *Science*. 2018;360:eaap8757.
- Mah W, Won H. The three-dimensional landscape of the genome in human brain tissue unveils regulatory mechanisms leading to schizophrenia risk. *Schizophr Res*. 2020;217:17–25.
- Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat Genet*. 2013;45:1150–9.
- Szatkiewicz JP, O'Dushlaine C, Chen G, Chambert K, Moran JL, Neale BM, et al. Copy number variation in schizophrenia in Sweden. *Mol Psychiatry*. 2014;19:762–73.
- Lichtenstein P, De Faire U, Floderus B, Svartengren M, Svedberg P, Pedersen NL. The Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies. *J Intern Med*. 2002;252:184–205.
- Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, et al. High-coverage whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios. *Cell*. 2022;185:3426–40.
- Dolzhenko E, Bennett MF, Richmond PA, Trost B, Chen S, van Vugt J, et al. ExpansionHunter Denovo: a computational method for locating known and novel repeat expansions in short-read sequencing data. *Genome Biol*. 2020;21:102.
- Ester Martin, K H-P, Sander Jiirg, Xu Xiaowei. A density-based algorithm for discovering clusters in large spatial databases with noise. *KDD-96 Proc*. 1996;96:226–31.
- Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genome-wide association scans. *Bioinformatics*. 2010;26:2190–1.
- Zoonomia C. A comparative genomics multitool for scientific discovery and conservation. *Nature*. 2020;587:240–5.
- Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. *Genome Res*. 2005;15:1034–50.
- Bryois J, Garrett ME, Song L, Safi A, Giusti-Rodriguez P, Johnson GD, et al. Evaluation of chromatin accessibility in prefrontal cortex of individuals with schizophrenia. *Nat Commun*. 2018;9:3121.
- Consortium EP. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012;489:57–74.
- Giusti-Rodriguez PMD, Sullivan PF. Using three-dimensional regulatory chromatin interactions from adult and fetal cortex to interpret genetic results for psychiatric disorders and cognitive traits. *bioRxiv* <https://doi.org/10.1101/406330>.
- Girdhar K, Hoffman GE, Jiang Y, Brown L, Kundakovic M, Hauberg ME, et al. Cell-specific histone modification maps in the human frontal lobe link schizophrenia risk to the neuronal epigenome. *Nat Neurosci*. 2018;21:1126–36.
- Hu B, Won H, Mah W, Park RB, Kassim B, Spiess K, et al. Neuronal and glial 3D chromatin architecture informs the cellular etiology of brain disorders. *Nat Commun*. 2021;12:3968.
- Skene NG, Bryois J, Bakken TE, Breen G, Crowley JJ, Gaspar HA, et al. Genetic identification of brain cell types underlying schizophrenia. *Nat Genet*. 2018;50:825–33.
- Handt M, Epplen A, Hoffjan S, Mese K, Epplen JT, Dekomien G. Point mutation frequency in the FMR1 gene as revealed by fragile X syndrome screening. *Mol Cell Probes*. 2014;28:279–83.
- Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. *Nat Neurosci*. 2016;19:1442–53.
- Wang D, Liu S, Warrell J, Won H, Shi X, Navarro FCP, et al. Comprehensive functional genomic resource and integrative model for the human brain. *Science*. 2018;362:eaat8464.
- Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubeis S, An JY, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *Cell*. 2020;180:568–84.e523.
- Kochinke K, Zweier C, Nijhof B, Fenckova M, Cizek P, Honti F, et al. Systematic phenomics analysis deconvolutes genes mutated in intellectual disability into biologically coherent modules. *Am J Hum Genet*. 2016;98:149–64.
- Kaplanis J, Samochoa KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al. Integrating healthcare and research genetic data empowers the discovery of 49 novel developmental disorders. *bioRxiv preprint* <https://doi.org/10.1101/797787>.

45. Bragin E, Chatzimichali EA, Wright CF, Hurler ME, Firth HV, Bevan AP, et al. DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variation. *Nucleic Acids Res.* 2014;42:D993–D1000. (Database issue)
46. Coe BP, Witherspoon K, Rosenfeld JA, van Bon BW, Vulto-van Silfhout AT, Bosco P, et al. Refining analyses of copy number variation identifies specific genes associated with developmental delay. *Nat Genet.* 2014;46:1063–71.
47. Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B, Morgen K, Arnarsdottir S, et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. *Nature.* 2014;505:361–6.
48. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020;581:434–43.
49. Amemiya HM, Kundaje A, Boyle AP. The ENCODE blacklist: identification of problematic regions of the genome. *Sci Rep.* 2019;9:9354.
50. McMurray CT. Mechanisms of trinucleotide repeat instability during human development. *Nat Rev Genet.* 2010;11:786–99.

ACKNOWLEDGEMENTS

This project is funded by NIMH R01 MH106611 relating to National Institute of Mental Health (to J.P.S.) and SciLifeLab National Project under the project identifier 2015-R2 (to PFS). PFS gratefully acknowledges support from the Swedish Research Council (Vetenskapsrådet, award D0886501). JW acknowledges support by a fellowship from the NHLBI BioData Catalyst program (1OT3HL142479-01, 1OT3HL142478-01, 1OT3HL142481-01, 1OT3HL142480-01, 1OT3HL147154). PGR was supported by NIMH K01 MH109772. YL is supported by R01MH12523 (to PFS). HW acknowledges DP2MH122403 and U01MH122509. The Sweden Schizophrenia Study was supported by NIMH R01 MH077139 (to PFS). Prior whole genome sequencing of the Swedish schizophrenia cases and controls was supported by National Genomics Infrastructure (NGI) Sweden, Science for Life Laboratory, the Swedish Research Council and the Knut and Alice Wallenberg Foundation. The SweGen Project was funded by Science for Life Laboratory (SciLifeLab) as a National Project, supported by the Knut and Alice Wallenberg Foundation (2014.0272), and The National Research Council (PI: UG). We acknowledge The Swedish Twin Registry for access to data. The Swedish Twin Registry is managed by Karolinska Institutet and receives funding through the Swedish Research Council under the grant number 2017-00641. The computations/data handling/[SIMILAR] were/was enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at [SNIC CENTER] partially funded by the Swedish Research Council through grant agreement no. 2018-05973. RKCY is supported by The Hospital for Sick Children's Research Institute, SickKids Catalyst Scholar in Genetics, Brain Canada, The Azrieli Foundation, the University of Toronto McLaughlin Center and the Nancy E.T. Fahrner Award. This work was also supported by the Canadian Institutes of Health Research (CIHR) (PJT-175329 to RKCY; PJT-178161 to RKCY and ASB; MOP-89066 and MOP-111238 to ASB). BT was funded by the Canadian Institutes for Health Research Banting Postdoctoral Fellowship and the Brain Canada Canadian Open Neuroscience Platform Research Scholar Award. A.S.B. holds the Dalgligh Family Chair in 22q11.2 Deletion Syndrome at the University Health Network and University of Toronto.

AUTHOR CONTRIBUTIONS

The study was designed by JPS and RKCY. Funding was obtained by JPS, PFS and RKCY. Statistical analysis was performed by JW, B Trost, WE, MH, JPS, and RKCY. Experimental validation was performed by NA., MF, LMP, AM, KG, and IB. PGR provided annotations for CTCF and boundaries of topologically associating domains from human adult brain. HW provided annotations for Hi-C enhancer-promoter anchors from human brain. PFS, GP, JDR, YL, and B Thiruvahindrapuram provided bioinformatics assistance. PKEM, UG, and the SweGen Project provided SweGen data. CMH and PFS provided the Swedish schizophrenia samples. ASB provided the Canadian schizophrenia samples used for replication. JW and JPS wrote the manuscript. B Trost, WE, MF, and RKCY contributed to writing. All authors reviewed and approved the final version of the manuscript.

COMPETING INTERESTS

PF Sullivan reports the following potentially competing financial interests: Neumora (advisory board, shareholder). The other authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41380-022-01857-4>.

Correspondence and requests for materials should be addressed to Ryan K. C. Yuen or Jin P. Szatkiewicz.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022